Innate Pharma SA

Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
  • TickerIPH
  • ISINFR0010331421
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alain William ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Martial Descoutures
  • Nicolas David
  • Olivier Lebrun
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 01/29/2019

...

Martial Descoutures ...
  • Pierre Corby

Innate Pharma : Fast track status for IPH4102

>FDA awards fast track status to IPH4102 in Sezary syndrome - Innate Pharma announced this morning that the FDA has granted fast track status for IPH4102 in patients with relapsed or refractory Sezary syndrome (SS) who have received at least two prior treatments. This FDA-approved status is intended to accelerate the development and review of treatments that address important and unmet medical needs. Sezary syndrome is a rare case of cutaneous T-type lymphoma (CTCL) ...

Alain William ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Martial Descoutures
  • Nicolas David
  • Olivier Lebrun
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 29/01/2019

...

Alain William ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Martial Descoutures
  • Nicolas David
  • Olivier Lebrun
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 01/29/2019

...

Martial Descoutures ...
  • Pierre Corby

Innate Pharma : Fast track status for IPH4102

>FDA awards fast track status to IPH4102 in Sezary syndrome - Innate Pharma announced this morning that the FDA has granted fast track status for IPH4102 in patients with relapsed or refractory Sezary syndrome (SS) who have received at least two prior treatments. This FDA-approved status is intended to accelerate the development and review of treatments that address important and unmet medical needs. Sezary syndrome is a rare case of cutaneous T-type lymphoma (CTCL) ...

Alain William ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Martial Descoutures
  • Nicolas David
  • Olivier Lebrun
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 29/01/2019

...

Martial Descoutures ...
  • Pierre Corby

Innate Pharma : Statut Fast Track pour IPH4102

>La FDA accorde le statut de Fast Track pour IPH4102 dans le syndrome de Sézary - Innate Pharma annonce ce matin l’obtention du statut de Fast Track par la FDA pour IPH4102 chez les patients atteints d’un syndrome de Sézary (SS) en rechute ou réfractaire ayant reçu au moins 2 traitements antérieurs. Ce statut accordé par la FDA vise à accélérer le développement et la revue de traitements répondant à des besoins médicaux importants et non satisfaits. Le syndrome de Séz...

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

1 director sold

A director at Innate Pharma sold 18,000 shares at 7.430EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

INNATE PHARMA sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of INNATE PHARMA (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date December 28, 2018, the closing price was EUR 7.44 and its target price was estimated at EUR 5.44.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Eric Le Berrigaud

Pharmaceuticals | ESMO 2018: Sequencing Was the Key Word

We synthesise here the main take-away messages from the annual ESMO congress which took place in Munich in October. We present the conclusions in sections organised by organ with three main parts: renal-cell carcinoma (RCC), breast cancer (BC) and lung cancer (NSCLC) with non-uniform levels of innovation and progress. The last section is dedicated to head & neck cancer with encouraging updated data on monatuximab/cetuxima

Jehanne Leroy

Proxy Report - 29/05/2018

Le principal sujet de la présente assemblée est la résolution 33 qui propose la création d'un droit de vote double alors même que la société avait proposé en 2015 une résolution afin de maintenir le principe "Une Action - Une Voix".  Proxinvest considère que le droit de vote double est une rupture grave du principe d'égalité des actionnaires. Cette rupture de l’égalité entre les actionnaires est double puisque, dans un premier temps, les actionnaires au nominatif et ceux au porteur ne sont plus soumis aux mêmes traitements, les actionnaires au porteur n’ayant aucune possibilité d’accéder au d...

Jehanne Leroy

Etude de l'AG du 23/06/2017

Les deux principaux sujets de la présente assemblée sont d'une part le renouvellement de tous les membres du conseil (résolutions 6 à 13) ainsi que les rémunérations (résolutions 16 à 24 et 26 à 31). Le recours à une structure duale assure la séparation des fonctions entre direction et supervision, le conseil est en majorité indépendant (62,5%) et aucun membre ne semble être en situation de cumul de mandat. Ainsi, tous les renouvellements et nominations proposés sont soutenus. Concernant les rémunérations, la principale faiblesse identifiée demeure le Golden Hello tel que pratiqué par la soc...

Matthieu DRIOL

Short term view - INNATE PHARMA SA : Prices are making further progress.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La progression des cours se poursuit.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - INNATE PHARMA SA : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

Valérie GASTALDY

Medium term view - INNATE PHARMA SA : The bounce is gaining strength.

The trend is bearish. The bounce is gaining strength. The bounce might end at the resistance at €6.900 and prices would fall again toward €4.171. The background trend would be questioned should prices rise above €6.900.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch